The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bevacizumab (Bmab) in combination with uracil-tegafur (UFT) and oral leucovorin (LV) in elderly patients (≥ 75 years old) with metastatic colorectal cancer (mCRC): A multicenter phase II trial (J-BLUE study).
Mitsuo Shimada
Research Funding - Chugai Pharma; Taiho Pharmaceutical
Tomohiro Nishina
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Jun Higashijima
No relevant relationships to disclose
Toshikazu Moriwaki
Research Funding - Taiho Pharmaceutical
Toshiki Masuishi
No relevant relationships to disclose
Yoshinori Sakai
No relevant relationships to disclose
Mitsuharu Ozeki
No relevant relationships to disclose
Yuji Negoro
No relevant relationships to disclose
Shunju Indou
No relevant relationships to disclose
Tadamichi Denda
No relevant relationships to disclose
Mikio Sato
No relevant relationships to disclose
Masamitsu Morimoto
No relevant relationships to disclose
Go Nakajima
No relevant relationships to disclose
Minoru Mizuta
No relevant relationships to disclose
Ikuo Takahashi
No relevant relationships to disclose
Yoshinori Hiroshima
No relevant relationships to disclose
Hiroyasu Ishida
No relevant relationships to disclose
Takashi Maeba
No relevant relationships to disclose
Ichinosuke Hyodo
Consultant or Advisory Role - Chugai Pharma; Taiho Pharmaceutical
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Research Funding - Chugai Pharma; Taiho Pharmaceutical